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Objectives
At the conclusion of this session, the participant 
will be able to:
Understand the latest estimates for birth defects associated 
with Zika virus infection during pregnancy.
Discuss additional considerations for evaluating and 
managing infants with possible congenital Zika virus 
infection.
Apply the updated recommendations outlined in the 
additional considerations for the evaluation and 
management of infants with possible congenital Zika virus 
infection.
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US Zika Pregnancy Registry
Purpose of registry
» To monitor pregnancy and infant outcomes in 
pregnancies with laboratory evidence of possible Zika 
virus infection and to inform clinical guidance and 
public health response
• Estimate number of infants with birth defects
• Provide data to inform phenotype of congenital Zika 
syndrome
• Help ensure infants are linked to care 
US Zika Pregnancy Registry: Inclusion Criteria
Who is included
» Pregnant women in the United States with laboratory evidence of 
possible Zika virus infection (regardless of whether they have 
symptoms) and their exposed infants
» Infants with laboratory evidence of congenital Zika virus infection 
(regardless of whether they have symptoms) and their mothers
US Zika Pregnancy Registry: First Report
Among pregnancies in the United States with laboratory evidence of 
possible Zika virus infection
» 6% of fetuses or infants had birth defects potentially related to Zika virus
» Similar proportion of pregnancies with birth defects (≈6%) among 
symptomatic and asymptomatic pregnant women 
» Among women with infection in the 1st trimester of pregnancy, birth defects 
reported in 11%
Honein MA, Dawson AL, Petersen EE et al. Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy. JAMA. 2016 Dec 15 [Epub
ahead of print] 
Vital Signs MMWR: Update Previous Estimates
What is Added by this Report
This report features the latest data from the US Zika Pregnancy Registry
» Initial estimates were based on 442 completed pregnancies reported to 
the registry by September 22, 2016
» This Vital Signs report provides data on 972 completed pregnancies 
reported to the registry through December 27, 2016
» Analyzed subgroup of confirmed Zika virus infections
This is the largest series of infant outcomes among pregnant women 
with laboratory evidence of possible Zika that has been reported
USZPR Definition of Laboratory Confirmed Zika Infection
Zika virus infection can be confirmed by
» Zika virus RNA in any maternal or fetal/infant specimen detected by 
nucleic acid test (NAT) (e.g., rRT-PCR) OR 
» Positive or equivocal Zika virus IgM with Zika virus plaque reduction 
neutralization test (PRNT) titer ≥10 and dengue virus PRNT <10
USZPR Definition of Possible Recent Zika Infection
Laboratory evidence of possible recent Zika virus infection
» Recent Zika virus infection detected by a Zika virus RNA nucleic acid 
test (NAT, e.g., [RT-PCR]) on any maternal, placental, or fetal/infant 
specimen or
» Detection of recent Zika virus infection or recent unspecified 
flavivirus infection by serologic tests on a maternal or infant 
specimen 
• Either positive or equivocal Zika virus IgM AND Zika virus PRNT titer ≥10, 
regardless of dengue virus PRNT value; or
• Negative Zika virus IgM, AND positive or equivocal dengue virus IgM, 
AND Zika virus PRNT titer ≥10, regardless of dengue virus PRNT titer
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Postnatal Neuroimaging and Testing  
Baseline Prevalence of Birth Defects Observed with Zika
» Used data from birth defects surveillance systems in 
Massachusetts, North Carolina, and Atlanta, Georgia, 
during pre-Zika outbreak years (2013–2014)
» Prevalence of Zika-related birth defects before Zika 
outbreak in the Americas: 
3 out of every 1,000 births
» Proportion of infants with birth defects among 
completed pregnancies with confirmed Zika infection 
(2016):
24 out of every 250 completed pregnancies
Cragan JD, Mai CT, Petersen EE, et al. Baseline Prevalence of Birth Defects Associated with Congenital Zika Virus Infection — Massachusetts, North Carolina, and Atlanta, Georgia, 2013–2014. MMWR Morb Mortal Wkly
Rep 2017;66:219–222. DOI: http://dx.doi.org/10.15585/mmwr.mm6608a4
Reynolds MR, Jones AM, Petersen EE, et al. Vital Signs: Update on Zika Virus–Associated Birth Defects and Evaluation of All U.S. Infants with Congenital Zika Virus Exposure — U.S. Zika Pregnancy Registry, 2016. MMWR 
Morb Mortal Wkly Rep 2017;66:366-373.
Estimated
30-fold 
increase 
in Zika-related birth 
defects in pregnancies 
with confirmed Zika 
infection compared with 
pre-Zika years
Key Vital Signs Findings
States reported pregnant women
with evidence of Zika in 201644
Pregnant women with confirmed Zika had a 
fetus or baby with birth defects1 in 10
Babies with possible congenital Zika infection were 
reported to have received brain imaging after birth1 in 4
only
about
Key Vital Signs Findings 
972 pregnant women with evidence of Zika 
completed their pregnancies in 2016, and 
some had babies with Zika-related birth 
defects:
» 5% with possible Zika had birth defects 
» 10% with confirmed Zika had birth 
defects 
» 15% with confirmed Zika in the first 
trimester had birth defects 
Preventing Zika in Pregnant Women 
What You Can Do to Help
Educate families on Zika prevention
Ask about Zika
Provide all needed tests and follow-up care
Support infants and families
Do Not Travel to Areas with Risk of Zika
» Pregnant women should not travel to 
areas with risk of Zika
http://wwwnc.cdc.gov/travel/page/zika-information
World Map
http://www.cdc.gov/zika/geo/active-countries.html 
There are currently 63 countries 
and territories worldwide, 
including 49 countries and 
territories in the Americas, with a 
CDC Zika Travel Notice. 
Countries with endemic Zika also 
pose a risk. 
As of April 24, 2017
Do Not Travel to Areas with Risk of Zika
If a pregnant woman must travel, she should
» Talk with her healthcare provider before she 
goes
» Strictly follow steps to prevent mosquito 
bites during the trip
» Take steps to prevent sexual transmission
» Talk with her healthcare provider after she 
returns, even if she doesn’t feel sick
http://wwwnc.cdc.gov/travel/page/zika-information
Prevent Mosquito Bites
If a pregnant woman lives in or travels to an area with Zika, 
she should
» Wear long-sleeved shirts and long pants
» Stay and sleep in places with air conditioning or that 
use window and door screens
» Use EPA-registered insect repellents with one of the 
following active ingredients:
• DEET, picaridin, IR3535, oil of lemon eucalyptus, para-
menthane-diol, or 2-undecanone
» Once a week, empty and scrub, turn over, cover, or 
throw out items that hold water, such as trash 
containers, tires, buckets, toys, planters, flowerpots, 
birdbaths or pools
Prevent Sexual Transmission of Zika Virus
A pregnant woman whose partner lives in or has 
traveled to an area with risk of Zika should
» Use condoms correctly every time they have sex, or
» Not have sex
For the duration of the pregnancy, even if the 
pregnant woman’s partner does not have 
symptoms or feel sick.
Healthcare Providers Caring for Pregnant Women and 
Infants Should Ask about Zika Exposure during Pregnancy
Have you traveled to 
an area with risk of 
Zika during pregnancy 
or just before you 
became pregnant?
Have you had sex 
without a condom 
with a partner who 
lives in or traveled to 
an area with risk of 
Zika?
Do you live in or do 
you frequently travel 
(daily or weekly) to 
an area with risk of 
Zika?
Who Should Be Tested for Zika?
All pregnant women (regardless of symptoms) who 
» Live in or recently traveled to an area with risk of Zika 
that has a CDC Zika travel notice, or 
» Had unprotected sex with a partner who lives in or 
traveled to an area with risk of Zika that has a CDC Zika 
travel notice
Pregnant women who live in or recently traveled to an 
area with risk of Zika but without a CDC Zika travel notice
» If they develop symptoms of Zika, or 
» If their fetus has abnormalities on an ultrasound that 
may be related to Zika infection
https://www.cdc.gov/zika/hc-providers/pregnant-women/testing-pregnant-women.html
Testing Infants for Zika
CDC recommends laboratory testing for
» All infants born to mothers with laboratory 
evidence of Zika virus infection during 
pregnancy
» Infants who have abnormal clinical or 
neuroimaging findings suggestive of 
congenital Zika syndrome and a mother 
with a possible exposure to Zika virus, 
regardless of maternal Zika virus testing 
results
Pediatric Evaluation and Follow-Up: The First 12 Months
Link to updated infant guidance (April 2017): https://www.cdc.gov/zika/hc-providers/infants-children/evaluation-and-
management.html?permalink=https://www.cdc.gov/zika/hc-providers/infants-children/evaluation-and-management.html
Contribute to the US Zika Pregnancy Registry 
Notify health department of pregnant women and/or infants with            
Zika virus infection 
» More information available on the U.S. Zika Pregnancy Registry website
» To contact CDC Registry staff, call the CDC Emergency Operations 
Center watch desk at 770-488-7100 and ask for the Zika Pregnancy 
Hotline or email ZIKApregnancy@cdc.gov.
» For non-urgent requests, call 800-CDC-INFO (800-232-4636) 
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
Thank you!
For more information, please visit:
www.cdc.gov/vitalsigns/index.html
www.cdc.gov/zika
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Evaluation and Management of Infants 
with Possible Congenital Zika Virus Infection
http://www.cdc.gov/mmwr/volumes/65/wr/mm6533e2.htm?s_cid=mm6533e2_w
Update Posted April 2017: Additional Considerations
• Additional Considerations for Evaluation and Management of 
Infants with Possible Zika Virus Infection
» Neuroimaging 
» Zika virus testing
https://www.cdc.gov/zika/hc-providers/infants-children/evaluation-and-management.html
Infants with Possible Congenital Zika Virus Infection
• Born to mothers with laboratory evidence of 
possible Zika virus infection
• With abnormal clinical  or neuroimaging findings 
suggestive of congenital Zika syndrome and a 
maternal epidemiologic link*
*An epidemiologic link includes travel to or residence in an area with risk of Zika, or
sex without a condom with a partner who traveled to or lived in such an area
Initial Evaluation of Infants 
with Possible Congenital Zika Virus Infection
• Comprehensive physical exam
» Head circumference, weight, length measurements
» Neurologic assessment
• Standard newborn hearing assessment
• Head ultrasound
• Zika virus laboratory testing
Initial Evaluation of Infants 
with Possible Congenital Zika Virus Infection continued
• Comprehensive physical exam
» Head circumference, weight, length measurements
» Neurologic assessment
• Standard newborn hearing assessment
• Head ultrasound
• Zika virus laboratory testing
Congenital Zika Syndrome
• Distinct pattern of birth defects in fetuses and 
infants of women infected during pregnancy
• Birth defects that make up the congenital Zika
syndrome
» Severe microcephaly with partially collapsed skull
» Thin cerebral cortex with subcortical calcifications
» Macular scarring and focal pigmentary retinal 
mottling
» Congenital contractures
» Marked early hypertonia and symptoms of 
extrapyramidal involvement
Congenital Zika Syndrome without Microcephaly at Birth
• Microcephaly from congenital infection can occur after birth
• The full spectrum of poor outcomes caused by Zika virus infection 
during pregnancy remains unknown
Linden V, Pessoa A, Dobyns WB, et al. Description of 13 Infants Born During October 2015–January 2016 . . . MMWR. 22 Nov 2016. 
New Vital Signs Report
Zika Virus: Protecting Pregnant Women and Babies
States reported pregnant women
with evidence of Zika in 201644
Pregnant women with confirmed Zika had a 
fetus or baby with birth defects1 in 10
Babies with possible congenital Zika infection were 
reported to have received brain imaging after birth1 in 4
only
about
Infants with Possible Congenital Zika Virus Infection: 
Neuroimaging
Current Interim Guidance
• A head ultrasound is 
recommended before hospital 
discharge for infants with 
possible Zika virus infection 
Infants with Possible Congenital Zika Virus Infection: 
Neuroimaging continued
Current Interim Guidance
• A head ultrasound is 
recommended before hospital 
discharge for infants with 
possible Zika virus infection 
Additional Considerations
• For an infant with a small or 
absent anterior fontanelle and 
poor visualization of the 
intracranial anatomy on 
ultrasound, other imaging should 
be considered
Initial Evaluation of Infants 
with Possible Congenital Zika Virus Infection 
• Comprehensive physical exam
» Head circumference, weight, length measurements
» Neurologic assessment
• Standard newborn hearing assessment
• Head ultrasound
• Zika virus laboratory testing
Laboratory Testing of Infants 
with Possible Congenital Zika Virus Infection
Current Interim Guidance
Testing for Zika virus infection is 
recommended for infants 
• Born to mothers with laboratory 
evidence of possible Zika virus 
infection
• With clinical or neuroimaging findings 
suggestive of congenital Zika 
syndrome and a maternal 
epidemiologic link*
*An epidemiologic link includes travel to or residence in an area with risk of Zika, or sex without a condom with a partner who traveled to or lived in such an area
Laboratory Testing of Infants 
with Possible Congenital Zika Virus Infection 
Current Interim Guidance
Testing for Zika virus infection is 
recommended for infants 
• Born to mothers with laboratory 
evidence of possible Zika virus 
infection
• With clinical or neuroimaging findings 
suggestive of congenital Zika 
syndrome and a maternal 
epidemiologic link*
Additional Considerations
Testing for Zika virus infection should 
be considered for infants
• Born to mothers with an epidemiologic 
link for whom
» There is concern about infant follow-up care
» Maternal testing was not performed before 
delivery and exposure was >12 weeks before 
delivery, or
» Maternal testing was negative but was 
performed on a specimen obtained >12 
weeks after maternal exposure
*An epidemiologic link includes travel to or residence in an area with risk of Zika, or sex without a condom with a partner who traveled to or lived in such an area
Timing of Laboratory Testing of Infants 
with Possible Congenital Zika Virus Infection
Current Interim Guidance
• CDC recommends testing 
specimens collected from infants 
within 2 days after birth. 
» If specimens are collected later, it 
may be difficult to distinguish 
congenital from postnatally 
acquired infection in areas with 
risk of Zika. 
Timing of Laboratory Testing of Infants 
with Possible Congenital Zika Virus Infection 
Current Interim Guidance
• CDC recommends testing 
specimens collected from infants 
within 2 days after birth. 
» If specimens are collected later, it 
may be difficult to distinguish 
congenital from postnatally 
acquired infection in areas with 
risk of Zika
Additional Considerations
• Testing specimens collected 
within the first few weeks to 
months after birth may still be 
useful in the evaluation for infants 
with possible congenital Zika virus 
infection, particularly among 
infants born in areas without risk 
of Zika
Testing of Cerebrospinal Fluid (CSF) 
Current Interim Guidance
• If cerebrospinal fluid (CSF) is obtained for other studies, Zika NAT 
(nucleic acid testing) for Zika virus RNA and Zika virus IgM should be 
performed on CSF
Testing of Cerebrospinal Fluid (CSF)  
Current Interim Guidance
• If cerebrospinal fluid (CSF) is 
obtained for other studies, NAT 
testing for Zika virus RNA and Zika 
virus IgM should be performed on 
CSF
Additional Considerations
• Testing CSF for Zika virus RNA and 
IgM antibody should be 
considered for infants with clinical 
findings of possible congenital 
Zika syndrome but whose initial 
laboratory tests are negative on 
serum and urine
Interpretation of Laboratory Test Results of Infants with 
Possible Congenital Zika Virus Infection
https://www.cdc.gov/zika/pdfs/pediatric-evaluation-follow-up-tool.pdf 
Laboratory Testing for Infants with 
Possible Congenital Zika Virus Infection
• Plaque Reduction Neutralization Test (PRNT) can be performed at 
18 months to confirm a congenital Zika virus infection after 
maternal IgG has waned 
Possible Limitations of Infant Zika Virus Laboratory Testing
• Case reports of infants with clinical 
findings consistent with possible 
congenital Zika virus syndrome in 
whom Zika virus lab results were 
negative
• Potential explanations include
» The clinical findings are due to 
another cause
» Testing was incomplete, performed 
on suboptimal specimens, or 
performed too late 
» The fetus failed to mount an IgM 
antibody response
Maintain a Level of Suspicion
• For infants without laboratory evidence of Zika virus infection but 
for whom suspicion for congenital Zika virus infection remains, 
HCPs should
» Evaluate for other causes of congenital infection
» Consider an ophthalmology exam and auditory brainstem response 
(ABR) hearing test 
» Consider performing other evaluation and follow up in accordance 
with CDC interim guidance for the evaluation and management of 
infants with possible congenital Zika syndrome

Zika Care Connect: Improving Access to Clinical Services
• Provider Network for Families Affected by Zika
» Maternal-fetal medicine, mental health services, audiology, radiology, 
pediatric ophthalmology, pediatric neurology, developmental pediatrics, 
infectious disease, and endocrinology
• Laboratory Testing Web Portal for Healthcare Providers
» Identify laboratories offering Zika testing
HelpLine: 1-844-677-0447 (toll-free)
Website: www.zikacareconnect.org
Summary
• Infants with possible congenital Zika 
virus infection
» Neuroimaging 
» Criteria, timing, and specimens for Zika 
testing
» Possible limitations 
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
Thank you! 
For more information, please visit:
www.cdc.gov/vitalsigns/index.html
www.cdc.gov/zika
To Ask a Question
 Using the Webinar System
 Click the Q&A button in the webinar
 Type your question in the Q&A box
 Submit your question
Thank you for joining!
Centers for Disease Control and Prevention 
Atlanta, Georgia
http://emergency.cdc.gov/coca 
Today’s webinar  will be archived
When:  A few days after the live call
What:  All call recordings (audio, webinar, and 
transcript)
Where:  On the COCA Call webpage 
https://emergency.cdc.gov/coca/calls/2017/callinfo_050417.asp
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